Retinal Angiomatous Proliferation and Intravitreal Bevacizumab Injection.
10.3341/kjo.2007.21.4.213
- Author:
Jae Hoon KANG
1
;
Kyung Ah PARK
;
Song Ee CHUNG
;
Se Woong KANG
Author Information
1. Department of Ophthalmology, Samsung Medical Center, College of Medicine, Sungkyunkwan University, Seoul, Korea. swkang@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
Intravitreal bevacizumab injection;
Retinal angiomatous proliferation
- MeSH:
Aged;
Aged, 80 and over;
Angiogenesis Inhibitors/*administration & dosage;
Antibodies, Monoclonal/*administration & dosage;
Female;
Fluorescein Angiography;
Follow-Up Studies;
Fundus Oculi;
Humans;
Injections;
Male;
Middle Aged;
Retinal Neovascularization/complications/*drug therapy/pathology;
Treatment Outcome;
Vascular Endothelial Growth Factor A;
Visual Acuity;
Vitreoretinopathy, Proliferative/complications/*drug therapy/pathology;
Vitreous Body
- From:Korean Journal of Ophthalmology
2007;21(4):213-215
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the short-term efficacy and safety of intravitreal bevacizumab injection (IVBI) in patients with retinal angiomatous proliferation (RAP). METHODS: Seven eyes of 5 patients with RAP were included in this study. All of the eyes evidenced stage 2 RAP lesions, except for one eye with a stage 3 lesion. IVBI (1.25 mg/0.05 cc) were conducted at 4 or 6-week intervals. Complete ocular examinations, angiographic results and optical coherence tomographic findings before and after the IVBI were analyzed at baseline and upon the follow-up visits. RESULTS: Seven eyes were studied in 5 patients who had undergone IVBI. Partial (3 eyes) or complete (4 eyes) regression of RAP was noted after IVBI in all of the studied eyes. Visual acuity improved in 5 of the eyes, and was stable in 2 of the eyes. One eye evidenced severe intraocular inflammation after IVBI and a subsequent development of new RAP, which was controlled with vitrectomy and repeat IVBI. CONCLUSIONS: This treatment was effective over 6 months, stabilizing or improving visual acuity and reducing angiographic leakage. These short-term results suggest that IVBI may constitute a promising therapeutic option, particularly in the early stages of RAP.
